Bone Metastases, Lung Cancer
Conditions
Keywords
Lung cancer, Bone metastases, EGFR, KRAS, Bone biomarkers, Metabolic parameters
Brief summary
Mortality due to non small cell lung cancers is the first cause of cancer death in men around the world. Lung adenocarcinoma regularly induces bone metastases responsible for high morbidity and impaired life quality. Overall survival of these patients is poor. Thus the investigators aimed to identify if some bone and metabolic parameters were associated with overall survival. Patients and Methods POUMOS is a prospective cohort of patients suffering from adenocarcinoma lung cancers with a first bone metastasis (stage IV). All patients have a bone biopsy with molecular status characterization of the tumor for EGFR, KRAS, BRAF and ALK. Bone metastasis localizations are obtained by bone scintigraphy or FDG-PET/CT. Whole body composition is obtained by DEXA scan (Hologic®). The investigators assessed also fasting blood levels of bone and metabolic biomarkers. Survival analyses will be performed using a proportional hazard regression model.
Interventions
OTHERBone metastases biopsy
The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adults over 18 years * both gender * covered by the French National Insurance * first bone metastases of adenocarcinoma lung cancer (synchronous or metachrone)
Exclusion criteria
\- adenocarcinoma previously treated by systemic oncologic treatment (chemotherapy, targeted therapy, immunotherapy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum DKK1 | day 0 | Biomarkers are assessed at baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum HbA1C | day 0 | Biomarkers are assessed at baseline |
| urinary CTX | day 0 | Biomarkers are assessed at baseline |
| hip bone mass (g/cm²) | day 0 | Whole body densitometry is performed at baseline |
| mutational profile of the bone metastases | day 0 | Molecular characterization of the bone metastases by PCR (EGFR, KRAS, BRAF) and FISH (ALK) |
Countries
France
Outcome results
None listed